Navigation Links
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Date:7/10/2008

diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond to treatment, most eventually relapse and require subsequent treatment and few patients are ultimately cured of their disease.

About Proteolix

Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib (PR-171), is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit http://www.proteolix.com.

Contact information

Matthew Ferguson

investors@proteolix.com

650-266-2825


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... The U.S. Food and Drug Administration (FDA) ... option for the treatment of schizophrenia and manic or ... aged 13-17 years old. ,, The updated Zyprexa ... increased potential for weight gain and hyperlipidemia in adolescents ...
(Date:12/4/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... webcast. Principal investigators will discuss the data presentations ... featured at the 51st American Society of Hematology (ASH) ... a.m. CT/10:00 a.m. ET on Monday, December 7, 2009. ...
(Date:12/4/2009)... Chemistry World recently highlighted a new report ... America ( PhRMA ) that identifies 97 new drugs ... The report found that the 97 products in ... either in human clinical trials or awaiting approval by the ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study 5085 1InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study 5085 2Clipa for a Cure 3A New Pink Instant Handbag Hanger Benefits Breast Cancer Research 58508 1Clipa for a Cure 3A New Pink Instant Handbag Hanger Benefits Breast Cancer Research 58508 2BASF Podcast 3A The Chemical Reporter Why Does Fluoride Make Your Teeth Hard 3F 58504 1BASF Podcast 3A The Chemical Reporter Why Does Fluoride Make Your Teeth Hard 3F 58504 2BASF Podcast 3A The Chemical Reporter Why Does Fluoride Make Your Teeth Hard 3F 58504 3
... Survival vs. Interferon-Alpha, COLLEGEVILLE, Pa., Nov. 26 ... WYE ), announced today that the,European Commission has ... with advanced renal cell carcinoma (RCC),who have at ... is the only,approved cancer therapy that specifically inhibits ...
... VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH) today ... of Lenocta(TM) (sodium stibogluconate), a novel,protein tyrosine ... immune stimulant approved for the treatment of ... cancers. The open-label Phase IIa study is,designed ...
Other Medicine Technology:Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 2Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 3Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 4Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 5Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 6VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 2VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 3VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 4
(Date:12/5/2009)... NEW ORLEANS, Dec. 5 There have been significant ... leading experts continue to gain a better understanding of ... treatment options and provide patients with the best care. ... the American Society of Hematology explores optimal induction therapies ...
(Date:12/5/2009)... This Type of Blood Cancer Is Most Challenging-- ... Pediatric oncologists have identified specific genes, dubbed partner genes, ... form of leukemia in infants. By more accurately defining ... infants may benefit from particular treatments. ,, Oncologists ...
(Date:12/5/2009)... wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay ... 40th birthday without ever tying the knot, since research has ... folks. And, um, isn,t there something wrong with those who ... new study looking at psychological measures shows that never-married people ...
(Date:12/5/2009)... MAMA campaign is a collaborative effort by the ... Alliance of North America (MANA), Citizens for Midwifery ... American Registry of Midwives (NARM), and the Midwifery ... recent the efforts of The MAMA Campaign to ...
(Date:12/4/2009)... Care Investment Trust Inc. (NYSE: CRE ... Directors has declared a dividend of $0.17 per share of common ... common shareholders of record on December 14, 2009. ... Inc. is a real estate investment and finance company investing in ...
Breaking Medicine News(10 mins):Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
... 38 companies across U.S. involved as salmonella outbreak action continues; ... safe , , FRIDAY, Jan. 23 (HealthDay News) -- More than ... 38 companies have been recalled so far in the ongoing ... the U.S. health department,s Web site. , As the ...
... A coalition of Texas public health organizations ... the need for a comprehensive, statewide smoke-free workplace ... health hazards of secondhand smoke.(Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) ... health risks of secondhand smoke, the growing number ...
... Jan. 23 Anthem Blue Cross and Blue Shield,in ... than,$908,000 to support over 1,000 not-for-profit organizations in 2009 ... parent company of Anthem,Blue Cross and Blue Shield will ... more than $1.3 million. , ...
... Jan. 23, 2009 A therapy developed at UC Irvine ... first embryonic stem cell treatment tested in humans. , The ... work by a research team led by Hans Keirstead, co-director ... Center, for a clinical trial in patients with acute spinal ...
... , , FRIDAY, Jan. 23 (HealthDay News) -- Three conditions ... to sleep apnea, new studies show. , Insulin resistance, ... life were all found to be associated with ... to reports published in the February issue of the ...
... Index decreased 3.7 points to 45.7 in December, according to the ... by Harris Interactive(R) on behalf of Spherion Corporation, indicates that workers ... ability to find a new job. , , ... , Sixty-six percent of workers ...
Other Medicine News:Health News:More Than 200 Peanut Butter Products Now Under Recall 2Health News:More Than 200 Peanut Butter Products Now Under Recall 3Health News:Texas Public Health Groups Launch Ad Campaign About Need for Comprehensive, Statewide Smoke-Free Law 2Health News:Texas Public Health Groups Launch Ad Campaign About Need for Comprehensive, Statewide Smoke-Free Law 3Health News:Anthem Blue Cross and Blue Shield Associates Pledge More Than $900,000 to Community Organizations 2Health News:Anthem Blue Cross and Blue Shield Associates Pledge More Than $900,000 to Community Organizations 3Health News:UCI behind world's first embryonic stem cell study in humans 2Health News:Problems Tied to Obesity Also Seem to Affect Sleep 2Health News:Problems Tied to Obesity Also Seem to Affect Sleep 3Health News:Texas Employment Report: Employee Confidence Index Drops 2
6.5mm diameter handpiece; 75mm handle with grooves for grip; Standard male luer taper fits most cannula hub and female luer taper....
45 degree angled; 5mm from bend to tip; overall length excluding hub 16mm; In Stainless Steel...
3 Piece with .35mm Angled Point, Curved to Left, #8, Side Opening Irrigation, 40mm overall length; in stainless steel; 30cm Long Silicone Tubing with Connector....
Curved to the Left 9# with 30 cm long silicone tubing with connector; 40mm overall length; in stainless steel...
Medicine Products: